Drug Profile
Bimatoprost/timolol ocular insert - AbbVie
Alternative Names: Bimatoprost/timolol HELIOS™ insert - AbbVie; Timolol/bimatoprost ocular insert - AbbVieLatest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator ForSight VISION5
- Developer Allergan
- Class Amides; Antiglaucomas; Antihypertensives; Lipids; Morpholines; Propanolamines; Synthetic prostaglandins; Thiadiazoles
- Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2alpha receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glaucoma; Ocular hypertension
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 29 Aug 2019 Discontinued - Phase-I/II for Glaucoma in Panama (Ophthalmic)
- 29 Aug 2019 Discontinued - Phase-I/II for Ocular hypertension in Panama (Ophthalmic)